cabozantinib
Protein kinase inhibitors and activators - Cabozantinib is used in two forms. A capsule form is used since 2012 to treat medullary thyroid cancer and a tablet form is used since 2016 as a second line treatment for renal cell carcinoma.. Reference standards of Cabozantinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below
Cabozantinib L-Malate
Catalogue No.:PA 30 62590
CAS :
1140909-48-3
Molecular Formula : C32H30FN3O10
Molecular Weight : 635.59

